Clinical Trial Update: S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab in patients with various non-Hodgkin lymphomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma | Phase 2 | Status: COMPLETED